Plasticell, Kings College London to collaborate in blood platelet substitute trials

Thursday, April 20, 2017

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has partnered with King’s College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells. The work is supported by a MedCity research grant which funds collaboration between leading SMEs and academics from London universities.

[Read More]

Plasticell appoints Dr. Aaron T. T. Chuang as chief scientific officer

Monday, June 15, 2015

Plasticell, a regenerative medicine company utilizing combinatorial technologies for stem cell research and in developing cell therapies, has recruited Dr. Aaron Chuang to its executive management team in the role of chief scientific officer. Previously, Chuang was research director at the regenerative medicine unit of GlaxoSmithKline, where he worked for over 18 years. As Plasticell’s chief scientific officer, Chuang takes on responsibility for preclinical therapeutic programmes, scientific oversight of collaborations and alliances, as well as external scientific communications. 

[Read More]

Plasticell honored at R&D 100 Awards

Wednesday, November 2, 2011

For almost 50 years, the R&D 100 Awards have been recognizing the year’s best new high-technology products. Determined by a panel of experts chosen by R&D Magazine, the award is recognition that the selected product is one of the most important innovations of the year. Plasticell’s CombiCult was chosen as one of the hundred for 2011, which included only three technologies from the U.K.

[Read More]

Plasticell demerges to create regenerative drug discovery unit

Wednesday, April 13, 2011

London-based Plasticell, the biotechnology company developing stem cell technologies, has undergone a strategic re-structuring to enable the company to focus on its award winning CombiCult technology for stem cell differentiation. Consequently, Plasticell has demerged its regenerative drug discovery unit into a newly established company, Progenitor Labs.

[Read More]